Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Emtansine”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT02144012
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 49
Large-scale testing (Phase 3)Active Not RecruitingNCT04457596
What this trial is testing

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2 Positive Breast Carcinoma+4 more
Alliance for Clinical Trials in Oncology 1,056
Early research (Phase 1)Study completedNCT01816035
What this trial is testing

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
HER2/Neu PositiveRecurrent Breast CarcinomaStage IIIB Breast Cancer+2 more
University of Washington 13
Testing effectiveness (Phase 2)Study completedNCT00679341
What this trial is testing

The Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Who this might be right for
Breast Cancer
Hoffmann-La Roche 137
Not applicableLooking for participantsNCT06693037
What this trial is testing

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,092
Large-scale testing (Phase 3)Looking for participantsNCT06846437
What this trial is testing

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Who this might be right for
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Shanghai JMT-Bio Inc. 228
Testing effectiveness (Phase 2)Study completedNCT00679211
What this trial is testing

Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 110
Large-scale testing (Phase 3)Looking for participantsNCT05288777
What this trial is testing

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IBreast Cancer Stage II+1 more
University of Virginia 45
Testing effectiveness (Phase 2)WithdrawnNCT03203616
What this trial is testing

Kadcyla In pAtients With bRAin Metastasis

Who this might be right for
Metastatic HER2-positive Breast Cancer With Brain Metastasis
Jules Bordet Institute
Testing effectiveness (Phase 2)Ended earlyNCT01702558
What this trial is testing

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Who this might be right for
Breast CancerGastric Cancer
Hoffmann-La Roche 182
Large-scale testing (Phase 3)Active Not RecruitingNCT06126640
What this trial is testing

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Who this might be right for
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. 1,615
Testing effectiveness (Phase 2)Looking for participantsNCT05408845
What this trial is testing

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Who this might be right for
Metastatic Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8+2 more
NRG Oncology 146
Early research (Phase 1)Study completedNCT02038010
What this trial is testing

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerStage IIIA Breast Cancer+3 more
Northwestern University 17
Not applicableStudy completedNCT05945927
What this trial is testing

Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 178
Large-scale testing (Phase 3)Active Not RecruitingNCT04622319
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Who this might be right for
HER2-Positive Primary Breast CancerResidual Invasive Breast Cancer
Daiichi Sankyo 1,600
Not applicableStudy completedNCT05735392
What this trial is testing

Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 48
Testing effectiveness (Phase 2)Ended earlyNCT03248492
What this trial is testing

DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Who this might be right for
Breast Cancer
Daiichi Sankyo 253
Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Large-scale testing (Phase 3)Looking for participantsNCT06830889
What this trial is testing

BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 1,450
Not applicableLooking for participantsNCT06928818
What this trial is testing

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Who this might be right for
Cancer of BreastTrastuzumab EmtansineTrastuzumab Deruxtecan
Seoul National University Hospital 100
Next Page